First person diagnosed with early stage pancreatic cancer in early detection study
Date:

The first patient to be diagnosed with early-stage pancreatic cancer after taking part in a trial of a new screening test says research is hugely important to help improve survival.
Roger Meekley, 74, had surgery to remove the cancer and is now undergoing chemotherapy treatment which it’s hoped will mean many more years with his loved ones.
Roger was one of the 800 participants in the pilot phase of a study run by researchers at the Cancer Research UK Southampton Clinical Trials Unit and University Hospital Southampton.
The trial is testing how well a new blood test can spot the signals of pancreatic cancer at an early stage. The Avantect test, developed by a US biotechnology company ClearNote Health, uses blood samples from people with a recent diagnosis of type 2 diabetes, a known risk factor and potential sign of pancreatic cancer.
Grandfather Roger, a retired engineer from Botley in Hampshire, was diagnosed with type two diabetes in February this year, and shortly afterwards was invited to take part in the SAFE-D study.
“Knowing someone who had died from pancreatic cancer and how nasty it was and how quickly it spread, I volunteered for the study straight away,” says Roger. “I was invited along to have a blood test and that was sent off. I then got a phone call from the trial team to say they were very sorry, but my test had come back positive.”